Microchip (MCHP) Q4 2026 earnings review
A Textbook V-Shaped Recovery
Microchip delivered a massive beat-and-raise quarter, definitively proving the cyclical bottom is in the rearview mirror. Q4 revenue surged 35% YoY to $1.31 billion, blowing past the $1.26 billion midpoint guidance. The combination of normalized channel inventory and rebounding end-market demand is driving powerful operating leverage: Non-GAAP EPS exploded to $0.57, well above the $0.50 guidance. With Q1 FY27 guided for another 11% sequential revenue jump and gross margins expanding past 62%, management's execution of their nine-point recovery plan is yielding phenomenal results.
🐂 Bull Case
Distributor inventory has dropped to 26 days (near historical lows), and internal inventory days fell from 201 to 185 sequentially. The destocking headwind has officially flipped to a restocking tailwind.
Non-GAAP gross margin has aggressively rebounded from 52.0% a year ago to 61.6% today, with guidance pushing it to ~62.75%. Factory utilization is rising, which directly absorbs fixed costs and lifts profitability.
🐻 Bear Case
Despite immense cash generation, the company remains scarred by previous high leverage. They returned $984 million to shareholders via dividends this year but executed zero share buybacks, focusing instead on balance sheet repair.
With Q1 FY27 CapEx guided to a meager $20 million, the company is still pausing most factory expansions. If demand continues to accelerate at an 11% sequential clip, Microchip risks running into severe supply constraints.
⚖️ Verdict: 🟢
Bullish. Microchip is executing a flawless cyclical rebound. Revenue is accelerating, margins are expanding rapidly, and demand visibility is improving across the board.
Key Themes
Data Center & AI Applications Accelerating
Microchip is seeing expanding design activity specifically in data center and AI end markets. The introduction and ramp of Gen6 PCIe retimer solutions are strengthening their high-speed connectivity portfolio. This mix shift toward complex system architectures provides a high-margin growth vector.
Inventory Normalization Fuels the Top Line
The massive inventory overhang that crushed FY25 has been cleared. From a peak in December 2024, the company has drained $320.9 million in inventory. Distributor inventory currently sits at a lean 26 days, driving strong expedite activity and forcing customers to place new orders rather than burn existing stock.
Operating Leverage Through Factory Utilization
As demand improves, Microchip is ramping both front-end and back-end factories. The non-GAAP operating margin has more than doubled YoY, rocketing from 14.0% in 25Q4 to 30.6% in 26Q4. This proves the immense leverage of their manufacturing model once underutilization charges fade.
CapEx Freeze Contradicts the Hyper-Growth Narrative
Despite a massive 35% YoY revenue surge and accelerating sequential growth, Q1 FY27 CapEx is guided to an incredibly low $20 million, with full-year FY27 CapEx targeted at just $100 million. Management explicitly notes they are 'pausing most of our factory expansion actions.' This contradicts the narrative of a robust, unbounded upcycle; if demand is truly soaring, starving the business of CapEx could trigger severe supply chain bottlenecks later this year.
Debt Phobia Stalls Buybacks
The scars of the 2024-2025 downturn remain visible in the capital allocation strategy. While the dividend provides a solid floor (paying out nearly $1B this year), management is refusing to allocate cash to share buybacks. They remain focused on debt reduction, leaving a powerful lever for EPS accretion untouched.
Macro and Geopolitical Headwinds
Management continues to flag macroeconomic risks, explicitly calling out potential tariffs from the US administration, inflation, and global geopolitical conflicts (Middle East, Ukraine). While currently masked by the inventory restocking cycle, these macro factors pose a structural risk to end-market consumption.
Other KPIs
Accelerating improvement. Inventory days dropped drastically from 201 days in December to 185 days in March. This aggressive internal destocking limits future inventory write-offs and frees up working capital.
Reversing. FCF grew 12.8% YoY despite the massive cyclical revenue trough at the beginning of the year. This was primarily driven by aggressive inventory liquidation, which effectively converted balance-sheet bloat into cash.
Guidance
Accelerating. The $1.456B midpoint implies an 11% sequential increase and a 35.3% jump YoY. This proves the recovery has legs beyond just a single quarter of channel refill.
Accelerating. Expanding from 61.6% in Q4. While still shy of the long-term 65% target, the steady sequential improvement highlights the math of higher factory utilization wiping out under-absorption charges.
Accelerating. The $0.69 midpoint is a 21% sequential jump from Q4's $0.57 and represents explosive YoY growth compared to previous quarters. It showcases the immense operating leverage inside Microchip's model.
Key Questions
CapEx Freeze vs. Demand Surge
You are guiding for an 11% sequential revenue jump, yet FY27 CapEx is strictly capped at $100M with most factory expansions paused. At what utilization level will you be forced to restart heavy CapEx to prevent choking off your own growth?
Timeline to 65% Gross Margin
With non-GAAP gross margin guided to ~62.75% next quarter, you are rapidly approaching your 65% target. Is this structurally achievable in FY27, or will product mix shifts limit the final leg of expansion?
Deleveraging Targets for Buybacks
The business is generating tremendous free cash flow, but buybacks remain paused. What specific net leverage ratio must be achieved before you consider reinstating the share repurchase program?